Samsung Active Asset Management Launches KoAct China Biohealthcare Active ETF, Benchmarking the Solactive China Biohealthcare Index
FRANKFURT AM MAIN – Solactive is pleased to announce its collaboration with Samsung Active Asset Management on the launch of the KoAct China Biohealthcare Active ETF, which uses the Solactive China Biohealthcare Index as a benchmark. The product aims to provide investors with targeted exposure to biohealthcare companies with a strong China and Hong Kong focus, reflecting the growing momentum of healthcare innovation and commercialization across the region.
The biohealthcare sector continues to undergo a rapid transformation as advances in biologics and novel therapies progress from research into broader clinical adoption. In China, the shift from generics toward innovative biologics is supported by structural tailwinds, including an aging population and rising prevalence of chronic diseases, reinforcing long-term demand for healthcare solutions. Regulatory reforms are also supporting innovation by improving review processes and accelerating development timelines, while the growing use of AI, real-world data, and digital tools is enhancing efficiency in drug discovery and development. As China and Hong Kong-listed companies become increasingly integrated into global biotech value chains, the segment is gaining relevance as a diversifying allocation beyond developed markets.
The Solactive China Biohealthcare Index is designed to reflect this growth story by selecting top 30 eligible companies from the Solactive GBS China All Cap USD Index and the Solactive GBS Hong Kong All Cap Index that are listed on the Hong Kong Stock Exchange and classified in relevant biohealthcare subindustries. Index eligibility requires a minimum share class market capitalization of USD 100 million and an average daily value traded of at least USD 1 million over the three months prior to selection, supporting investability. Constituents are selected by ranking securities by share class market capitalization, and the index applies a market capitalization-based weighting scheme, capping the three largest companies at 10% and all others at 3%, with quarterly rebalancing and monthly reweighting to maintain the intended exposures over time.
The ETF listed on 27 January 2026 on the Korea Exchange (KRX) under the ticker code “[0154H0]”.
Timo Pfeiffer, Chief Markets Officer at Solactive, commented: “Following the successful launch of Samsung Active Asset Management’s KoAct US Biohealthcare Active ETF last November, we are pleased to continue our collaboration by providing the benchmark for the new China-focused strategy. Biohealthcare innovation is inherently global, and this ETF gives investors access to companies positioned to benefit from China’s expanding role in advancing therapies and scaling commercialization.”
Hugh Cho, comments: “China in shifting from a fast follower to a disruptive innovator in biopharma and life sciences and we believe that this shift is secular.”